Pheon Therapeutics is a UK-based developer of antibody-drug conjugates developing a novel pipeline of next-generation ADCs with the potential to treat solid and liquid cancers that do not respond to other treatments. Recently, Pheon Therapeutics received $68 million in Series A financing, with investments from Research Corporation Technologies, Atlas Venture, Forbion Capital Partners, and Brandon Capital Partners.
This article is reproduced from: https://www.itjuzi.com/investevent/13586457
This site is for inclusion only, and the copyright belongs to the original author.